Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL CITRATE AND DROPERIDOL versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL CITRATE AND DROPERIDOL versus METHADOSE.
FENTANYL CITRATE AND DROPERIDOL vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a mu-opioid receptor agonist, producing analgesia and sedation. Droperidol is a butyrophenone antipsychotic that blocks dopamine D2 receptors in the brain, causing tranquilization and antiemetic effects.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Fentanyl 50-100 mcg IV and droperidol 2.5-5 mg IV, administered slowly over 1-2 minutes, repeated every 60 minutes as needed for breakthrough pain or sedation.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Fentanyl: 3-4 hours (terminal elimination half-life); prolonged in elderly and hepatic impairment. Droperidol: 2.2-2.5 hours (terminal elimination half-life).
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Fentanyl: primarily renal (75% as metabolites, <10% unchanged), with about 9% excreted in feces. Droperidol: renal (75% as metabolites, <1% unchanged), about 22% in feces.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist